Lv51
850 积分 2023-12-30 加入
Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment
7天前
已完结
CAR T-cell therapy in autoimmune diseases
8天前
已完结
Strategies to identify, engineer, and validate antibodies targeting blood–brain barrier receptor-mediated transcytosis systems for CNS drug delivery
11天前
已完结
Engineering T-cell receptor–like antibodies for biologics and cell therapy
13天前
已完结
Discovery and investigation of the truncation of the (GGGGS)n linker and its effect on the productivity of bispecific antibodies expressed in mammalian cells
13天前
已完结
Arginine Deprivation/Citrulline Augmentation with ADI-PEG20 As Novel Therapy for Complications in Type 2 Diabetes
14天前
已完结
Preclinical Study of a Novel Tri-Specific Anti-CD3/CD19/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHL
23天前
已完结
Preclinical Study of a Novel Tri-Specific Anti-CD3/CD19/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHL
23天前
已关闭
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
25天前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
25天前
已完结
皖公网安备34019202002308
